Form 4: Myriad Genetics CCO Brian Donnelly Acquires Shares

Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of Myriad Genetics common stock via the employee stock purchase plan.

Summary

• Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics, acquired 5,000 shares of common stock.
• The transaction occurred on June 11, 2026, at a price of $3.936 per share.
• Following this acquisition, the reporting person's total beneficial ownership increased to 573,363 shares.
• The acquisition was executed through the company's Amended and Restated 2012 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding executive equity ownership.

Positives

• Insider acquisition of 5,000 shares demonstrates management's continued investment in the company's equity.

Negatives

• None noted.

Risks

• None noted.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider participation in employee stock purchase plans is a standard corporate governance practice and generally reflects internal confidence in the company's long-term trajectory.

Comparison to Industry Standards

• The transaction is consistent with standard executive compensation and equity participation programs observed in the biotechnology sector.

Stakeholder Impact

• Shareholders may view the increased insider stake as a positive signal of management alignment.

Key Dates

Keywords

Myriad Genetics, MYGN, Insider Trading, Form 4, Stock Purchase Plan, Brian Donnelly